Se connecter

Bibliographies thématiques / Renal Protection / Articles de revues

Pour voir les autres types de publications sur ce sujet consultez le lien suivant : Renal Protection.

Articles de revues sur le sujet « Renal Protection »

Auteur : Grafiati

Publié le 7 juin 2025

Mis à jour le 2 août 2025

Créez une référence correcte selon les styles APA, MLA, Chicago, Harvard et plusieurs autres

Choisissez une source :

Consultez les 50 meilleurs articles de revues pour votre recherche sur le sujet « Renal Protection ».

À côté de chaque source dans la liste de références il y a un bouton « Ajouter à la bibliographie ». Cliquez sur ce bouton, et nous générerons automatiquement la référence bibliographique pour la source choisie selon votre style de citation préféré : APA, MLA, Harvard, Vancouver, Chicago, etc.

Vous pouvez aussi télécharger le texte intégral de la publication scolaire au format pdf et consulter son résumé en ligne lorsque ces informations sont inclues dans les métadonnées.

Parcourez les articles de revues sur diverses disciplines et organisez correctement votre bibliographie.

1

Mogensen, Carl Erik. "Renal protection." American Journal of Cardiovascular Drugs 4, Special Issue 1 (2004): 31–36. http://dx.doi.org/10.2165/00129784-200404991-00009.

Texte intégral

Styles APA, Harvard, Vancouver, ISO, etc.

2

Sadovnikoff, Nicholas, and Simon Gelman. "Renal protection." Best Practice & Research Clinical Anaesthesiology 14, no. 1 (2000): 161–71. http://dx.doi.org/10.1053/bean.2000.0068.

Texte intégral

Styles APA, Harvard, Vancouver, ISO, etc.

3

Sadovnikoff, Nicholas, and Simon Gelman. "Perioperative renal protection." Current Opinion in Anaesthesiology 12, no. 3 (1999): 337–41. http://dx.doi.org/10.1097/00001503-199906000-00015.

Texte intégral

Styles APA, Harvard, Vancouver, ISO, etc.

4

Canet, Emmanuel, and Rinaldo Bellomo. "Perioperative renal protection." Current Opinion in Critical Care 24, no. 6 (2018): 568–74. http://dx.doi.org/10.1097/mcc.0000000000000560.

Texte intégral

Styles APA, Harvard, Vancouver, ISO, etc.

5

Webb, Stephen T., and J. Stephen D. Allen. "Perioperative renal protection." Continuing Education in Anaesthesia Critical Care & Pain 8, no. 5 (2008): 176–80. http://dx.doi.org/10.1093/bjaceaccp/mkn032.

Texte intégral

Styles APA, Harvard, Vancouver, ISO, etc.

6

Jones, Dean R., and H. Thomas Lee. "Perioperative renal protection." Best Practice & Research Clinical Anaesthesiology 22, no. 1 (2008): 193–208. http://dx.doi.org/10.1016/j.bpa.2007.08.005.

Texte intégral

Styles APA, Harvard, Vancouver, ISO, etc.

7

Rodicio, Jose L., and Luis M. Ruilope. "Assessing renal effects and renal protection." Journal of Hypertension 13, supplement4 (1995): S19—S25. http://dx.doi.org/10.1097/00004872-199512002-00004.

Texte intégral

Styles APA, Harvard, Vancouver, ISO, etc.

8

Ruiz-Hurtado, Gema, and Luis M. Ruilope. "Does cardiovascular protection translate into renal protection?" Nature Reviews Cardiology 11, no. 12 (2014): 742–46. http://dx.doi.org/10.1038/nrcardio.2014.97.

Texte intégral

Styles APA, Harvard, Vancouver, ISO, etc.

9

UEKI, Masaaki. "Renal Protection Strategy for Ischemic Renal Dysfunction." JOURNAL OF JAPAN SOCIETY FOR CLINICAL ANESTHESIA 27, no. 7 (2007): 608–12. http://dx.doi.org/10.2199/jjsca.27.608.

Texte intégral

Styles APA, Harvard, Vancouver, ISO, etc.

10

Hoss, Molly, and Corey Lyon. "Empagliflozin for renal protection." Evidence-Based Practice 20, no. 8 (2017): E12. http://dx.doi.org/10.1097/01.ebp.0000541808.45899.70.

Texte intégral

Styles APA, Harvard, Vancouver, ISO, etc.

11

Maleck, Wolfgang H., Swen N. Piper, and Katharina P. Koetter. "Dopamine for renal protection." Canadian Journal of Anesthesia/Journal canadien d'anesthésie 50, no. 1 (2003): 93–94. http://dx.doi.org/10.1007/bf03020198.

Texte intégral

Styles APA, Harvard, Vancouver, ISO, etc.

12

Hashiguchi, Hideo, Hiroaki Morooka, and Koji Sumikawa. "Renal Protection with Isoflurane." Anesthesia & Analgesia 103, no. 4 (2006): 1054. http://dx.doi.org/10.1213/01.ane.0000239082.25563.06.

Texte intégral

Styles APA, Harvard, Vancouver, ISO, etc.

13

Lee, H. Thomas, and Charles W. Emala. "Renal Protection with Isoflurane." Anesthesia & Analgesia 103, no. 4 (2006): 1053–54. http://dx.doi.org/10.1213/01.ane.0000239084.72741.b2.

Texte intégral

Styles APA, Harvard, Vancouver, ISO, etc.

14

Amir, Rawan, Sara Suhl, and Charles M. Alexander. "Renal Evaluation and Protection." Clinics in Geriatric Medicine 36, no. 3 (2020): 431–45. http://dx.doi.org/10.1016/j.cger.2020.04.004.

Texte intégral

Styles APA, Harvard, Vancouver, ISO, etc.

15

Di Tomasso, Nora, Fabrizio Monaco, and Giovanni Landoni. "Renal protection in cardiovascular surgery." F1000Research 5 (March 11, 2016): 331. http://dx.doi.org/10.12688/f1000research.7348.1.

Texte intégral

Résumé :

Acute kidney injury (AKI) is one of the most relevant complications after major surgery and is a predictor of mortality. In Western countries, patients at risk of developing AKI are mainly those undergoing cardiovascular surgical procedures. In this category of patients, AKI depends on a multifactorial etiology, including low ejection fraction, use of contrast media, hemodynamic instability, cardiopulmonary bypass, and bleeding. Despite a growing body of literature, the treatment of renal failure remains mainly supportive (e.g. hemodynamic stability, fluid management, and avoidance of further

Styles APA, Harvard, Vancouver, ISO, etc.

16

MacIsaac, Richard J., George Jerums, and Elif I. Ekinci. "Cardio-renal protection with empagliflozin." Annals of Translational Medicine 4, no. 20 (2016): 409. http://dx.doi.org/10.21037/atm.2016.10.36.

Texte intégral

Styles APA, Harvard, Vancouver, ISO, etc.

17

Mori, Takefumi, Ikuko Yabana, Satoshi Kinugasa, Shinichi Sato, and Yoshitsugu Iwakura. "Renal protection on ascites control." Kanzo 58, no. 2 (2017): 78–84. http://dx.doi.org/10.2957/kanzo.58.78.

Texte intégral

Styles APA, Harvard, Vancouver, ISO, etc.

18

Salvetti, Antonio, Paola Mattei, and Isabella Sudano. "Renal Protection and Antihypertensive Drugs." Drugs 57, no. 5 (1999): 665–93. http://dx.doi.org/10.2165/00003495-199957050-00002.

Texte intégral

Styles APA, Harvard, Vancouver, ISO, etc.

19

Shehabi, Y. "Renal protection by N -acetylcysteine." British Journal of Anaesthesia 98, no. 2 (2007): 270–71. http://dx.doi.org/10.1093/bja/ael351.

Texte intégral

Styles APA, Harvard, Vancouver, ISO, etc.

20

Benigni, Ariela, Norberto Perico, and Giuseppe Remuzzi. "Endothelin Antagonists and Renal Protection." Journal of Cardiovascular Pharmacology 35 (2000): S75—S78. http://dx.doi.org/10.1097/00005344-200000002-00017.

Texte intégral

Styles APA, Harvard, Vancouver, ISO, etc.

21

Rodicio, Jose L., Jose M. Morales, Jose M. Alcazar, and Luis M. Ruilope. "Calcium antagonists and renal protection." Journal of Hypertension 11, Supplement 1 (1993): S49—S53. http://dx.doi.org/10.1097/00004872-199303001-00009.

Texte intégral

Styles APA, Harvard, Vancouver, ISO, etc.

22

Redon, Josep. "Renal protection by antihypertensive drugs." Journal of Hypertension 16, Supplement (1998): 2091–100. http://dx.doi.org/10.1097/00004872-199816121-00035.

Texte intégral

Styles APA, Harvard, Vancouver, ISO, etc.

23

Gelman, Simon. "Renal protection during surgical stress." Acta Anaesthesiologica Scandinavica 41, S110 (1997): 43–45. http://dx.doi.org/10.1111/j.1399-6576.1997.tb05495.x.

Texte intégral

Styles APA, Harvard, Vancouver, ISO, etc.

24

Rocca, Giorgio Della, Livia Pompei, Silvio Monaco, Maria Gabriella Costa, and Cecilia Coccia. "Renal Protection and Liver Transplantation." Anesthesiology 96, Sup 2 (2002): A415. http://dx.doi.org/10.1097/00000542-200209002-00415.

Texte intégral

Styles APA, Harvard, Vancouver, ISO, etc.

25

Tervaert, Jan-Willem Cohen, and Peter W. de Leeuw. "Renal protection from glomerular fibrosis." Journal of Hypertension 21, no. 4 (2003): 687–89. http://dx.doi.org/10.1097/00004872-200304000-00007.

Texte intégral

Styles APA, Harvard, Vancouver, ISO, etc.

26

Wang, Si-Yang, Guang-Yan Cai, and Xiang-Mei Chen. "Energy restriction in renal protection." British Journal of Nutrition 120, no. 10 (2018): 1149–58. http://dx.doi.org/10.1017/s0007114518002684.

Texte intégral

Résumé :

AbstractEnergy restriction (ER) has been widely studied as a novel intervention, and its ability to prolong life has been fully demonstrated. For example, ER can significantly extend the lifespans of model flies, worms, rodents and other mammals. The role of ER in renal protection has also been elucidated. In preclinical studies, adjusting total energy intake or consumption of specific nutrients has prophylactic or therapeutic effects on ageing-related kidney disease and acute and chronic kidney injury. Amino acid restriction has gradually attracted attention. ER mimetics have also been studie

Styles APA, Harvard, Vancouver, ISO, etc.

27

Ruilope, Luis M., and Julian Segura. "Renal protection by antihypertensive therapy." Current Hypertension Reports 4, no. 4 (2002): 324–28. http://dx.doi.org/10.1007/s11906-996-0012-0.

Texte intégral

Styles APA, Harvard, Vancouver, ISO, etc.

28

Neumayer, Hans-Hellmut, Jürgen Gellert, and Friedrich Cameron Luft. "Calcium Antagonists and Renal Protection." Renal Failure 15, no. 3 (1993): 353–58. http://dx.doi.org/10.3109/08860229309054944.

Texte intégral

Styles APA, Harvard, Vancouver, ISO, etc.

29

Giovanna, Leoncini, Viazzi Francesca, and Pontremoli Roberto. "RAAS Inhibition and Renal Protection." Current Pharmaceutical Design 18, no. 7 (2012): 971–80. http://dx.doi.org/10.2174/138161212799436520.

Texte intégral

Styles APA, Harvard, Vancouver, ISO, etc.

30

Colson, P. "ACE inhibitors and renal protection." British Journal of Anaesthesia 78, no. 4 (1997): 477–78. http://dx.doi.org/10.1093/bja/78.4.477.

Texte intégral

Styles APA, Harvard, Vancouver, ISO, etc.

31

Zarbock, Alexander, and Kindgen Milles. "Novel therapy for renal protection." Current Opinion in Anaesthesiology 28, no. 4 (2015): 431–38. http://dx.doi.org/10.1097/aco.0000000000000213.

Texte intégral

Styles APA, Harvard, Vancouver, ISO, etc.

32

Epstein, Murray. "Calcium Antagonists and Renal Protection." Archives of Internal Medicine 152, no. 8 (1992): 1573. http://dx.doi.org/10.1001/archinte.1992.00400200011003.

Texte intégral

Styles APA, Harvard, Vancouver, ISO, etc.

33

Patel, Pranav M., and Morton J. Kern. "Moving renal embolic protection forward." Catheterization and Cardiovascular Interventions 79, no. 3 (2012): 437–38. http://dx.doi.org/10.1002/ccd.24313.

Texte intégral

Styles APA, Harvard, Vancouver, ISO, etc.

34

Fukuda, M. "Antihypertensive Drugs and Renal Protection." JAMA: The Journal of the American Medical Association 289, no. 9 (2003): 1102—a—1103. http://dx.doi.org/10.1001/jama.289.9.1102-b.

Texte intégral

Styles APA, Harvard, Vancouver, ISO, etc.

35

Nespoux, Josselin, and Volker Vallon. "SGLT2 inhibition and kidney protection." Clinical Science 132, no. 12 (2018): 1329–39. http://dx.doi.org/10.1042/cs20171298.

Texte intégral

Résumé :

Type 2 diabetes mellitus (T2DM) is a growing public health concern worldwide. Numerous drug classes are available for treatment, however, their efficacy with regard to diabetes-induced renal and cardiovascular (CV) complications remains limited. Inhibitors of the sodium-glucose cotransporter 2 (SGLT2) are a new class of blood glucose lowering medications that block renal glucose reabsorption and have protective effects on the kidney and the heart. This review focusses on the effects of SGLT2 inhibitors on the kidney and renal outcome: it briefly outlines renal glucose handling in diabetes and

Styles APA, Harvard, Vancouver, ISO, etc.

36

Joo, Jin Deok, Mihwa Kim, Patrick Horst, et al. "Acute and delayed renal protection against renal ischemia and reperfusion injury with A1 adenosine receptors." American Journal of Physiology-Renal Physiology 293, no. 6 (2007): F1847—F1857. http://dx.doi.org/10.1152/ajprenal.00336.2007.

Texte intégral

Résumé :

We showed previously that activation of A1 adenosine receptors (AR) protects against renal ischemia-reperfusion (IR) injury in rats and mice. In the heart, transient A1AR activation produces biphasic protective effects: acute protection wanes after several hours but protective effects return 24–72 h later (second window of protection). In this study, we determined whether A1AR activation produces delayed renal protection and elucidated the mechanisms of acute and delayed renal protection. A1AR wild-type mice were subjected to 30-min renal ischemia and 24 h of reperfusion to produce acute renal

Styles APA, Harvard, Vancouver, ISO, etc.

37

Epstein, M. "Calcium antagonists and renal hemodynamics: implications for renal protection." Journal of the American Society of Nephrology 2, no. 2 (1991): S30. http://dx.doi.org/10.1681/asn.v22s30.

Texte intégral

Résumé :

During the past decade, attention has focused on the effects of calcium antagonists on renal function. When administered in vitro to the isolated perfused kidney, calcium antagonists exhibit consistent actions permitting characterization of their renal effects. Calcium antagonists do not affect the vasodilated isolated perfused kidney, but they do dramatically alter the response of this preparation to vasoconstrictor agents. Our recent studies with the isolated perfused hydronephrotic rat kidney model, which permits visualization of afferent and efferent arterioles, have demonstrated that the

Styles APA, Harvard, Vancouver, ISO, etc.

38

Taal, Maarten W., and Barry M. Brenner. "Achieving maximal renal protection in nondiabetic chronic renal disease." American Journal of Kidney Diseases 38, no. 6 (2001): 1365–71. http://dx.doi.org/10.1053/ajkd.2001.29259.

Texte intégral

Styles APA, Harvard, Vancouver, ISO, etc.

39

Brown, W. Virgil. "Microvascular Complications of Diabetes Mellitus: Renal Protection Accompanies Cardiovascular Protection." American Journal of Cardiology 102, no. 12 (2008): 10L—13L. http://dx.doi.org/10.1016/j.amjcard.2008.09.068.

Texte intégral

Styles APA, Harvard, Vancouver, ISO, etc.

40

Barrios, Vivencio, and Carlos Escobar. "Canagliflozin: metabolic, cardiovascular and renal protection." Future Cardiology 17, no. 3 (2021): 443–58. http://dx.doi.org/10.2217/fca-2020-0192.

Texte intégral

Résumé :

Patients with Type 2 Diabetes (T2D) are at risk of developing macrovascular (cardiac, cerebrovascular, peripheral arterial disease) and microvascular (nephropathy, neuropathy, retinopathy) complications. Glycemic control improves only microvascular outcomes. However, some SGLT-2 inhibitors and GLP1-R agonists have proven beneficial in macrovascular conditions. Canagliflozin is an SGLT2 inhibitor that provides sustained reductions in HbA1c, blood pressure and weight. Remarkably, as CANVAS program and CREDENCE trial demonstrated, canagliflozin promotes significant reductions in the frequency of

Styles APA, Harvard, Vancouver, ISO, etc.

41

Inoue, Tsuyoshi. "Neuroimmune system-mediated renal protection mechanisms." Clinical and Experimental Nephrology 25, no. 9 (2021): 915–24. http://dx.doi.org/10.1007/s10157-021-02062-3.

Texte intégral

Résumé :

AbstractThe autonomic nervous system plays an important role in maintaining homeostasis in organisms. Recent studies have shown that it also controls inflammation by directly altering the function of the immune system. The cholinergic anti-inflammatory pathway (CAP) is one of the neural circuits operating through the vagus nerve. Acetylcholine released from the terminal of the vagus nerve, which is a parasympathetic nerve, acts on the α7 nicotinic acetylcholine receptor of macrophages and reduces inflammation in the body. Previous animal studies demonstrated that vagus nerve stimulation reduce

Styles APA, Harvard, Vancouver, ISO, etc.

42

Kobori, Hiroyuki, Hirohito Mori, Tsutomu Masaki, and Akira Nishiyama. "Angiotensin II Blockade and Renal Protection." Current Pharmaceutical Design 19, no. 17 (2013): 3033–42. http://dx.doi.org/10.2174/1381612811319170009.

Texte intégral

Styles APA, Harvard, Vancouver, ISO, etc.

43

Meersch, Melanie, and Alexander Zarbock. "Renal protection in the 21st century." Current Opinion in Critical Care 22, no. 6 (2016): 554–59. http://dx.doi.org/10.1097/mcc.0000000000000352.

Texte intégral

Styles APA, Harvard, Vancouver, ISO, etc.

44

BOWSHER, W. G., P. BLOTT, and H. N. WHITFIELD. "Radiation Protection in Percutaneous Renal Surgery." British Journal of Urology 69, no. 3 (1992): 231–33. http://dx.doi.org/10.1111/j.1464-410x.1992.tb15518.x.

Texte intégral

Styles APA, Harvard, Vancouver, ISO, etc.

45

Mah??, Emmanuel, Emmanuel Morelon, Jacques Fermanian, et al. "Renal-Transplant Recipients and Sun Protection." Transplantation 78, no. 5 (2004): 741–44. http://dx.doi.org/10.1097/01.tp.0000131818.24302.b8.

Texte intégral

Styles APA, Harvard, Vancouver, ISO, etc.

46

Neumayer, Hans-Hellmut, and Ulrich Kunzendorf. "Renal Protection with the Calcium Antagonists." Journal of Cardiovascular Pharmacology 18 (1991): S11—S18. http://dx.doi.org/10.1097/00005344-199100181-00004.

Texte intégral

Styles APA, Harvard, Vancouver, ISO, etc.

47

Bhattacharjee, Rabindra N., Sanjay V. B. Patel, Qizhi Sun, et al. "Renal Protection Against Ischemia Reperfusion Injury." Transplantation 104, no. 3 (2020): 482–89. http://dx.doi.org/10.1097/tp.0000000000002967.

Texte intégral

Styles APA, Harvard, Vancouver, ISO, etc.

48

Giannopoulos, Georgios, Dimitrios A. Vrachatis, Vasiliki Panagopoulou, Manolis Vavuranakis, Michael W. Cleman, and Spyridon Deftereos. "Remote Ischemic Conditioning and Renal Protection." Journal of Cardiovascular Pharmacology and Therapeutics 22, no. 4 (2017): 321–29. http://dx.doi.org/10.1177/1074248417702480.

Texte intégral

Styles APA, Harvard, Vancouver, ISO, etc.

49

Neumayer, Hans-Hellmut, and Ulrich Kunzendorf. "Renal Protection with the Calcium Antagonists." Journal of Cardiovascular Pharmacology 18 (1991): S11—S18. http://dx.doi.org/10.1097/00005344-199106181-00004.

Texte intégral

Styles APA, Harvard, Vancouver, ISO, etc.

50

Wardle, Edwin N. "Renal protection in immunoglobulin-A nephropathy." Nephrology Dialysis Transplantation 21, no. 4 (2005): 1136. http://dx.doi.org/10.1093/ndt/gfi260.

Texte intégral

Styles APA, Harvard, Vancouver, ISO, etc.

Nous offrons des réductions sur tous les plans premium pour les auteurs dont les œuvres sont incluses dans des sélections littéraires thématiques. Contactez-nous pour obtenir un code promo unique!